In addition to increased tumor growth control, immunological analysis of the treated tumors revealed significant infiltration of CD4+, CD8+ as well as Trp2-specific CD8+ T cells into the TME of the PeptiBAC-Trp2+ICI-treated mice. The gene discussed is CD8A; the disease is neoplasm.